data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

NeuroMetrix

(NASDAQ:NURO)

Intraday

$4.63

0.19[4.28%]

15 minutes delayed

Perks Buy Compare Brokers

$4.63

0.19[4.28%]

Last update: 8:33AM Get Real Time Here

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for NeuroMetrix Stock (NASDAQ:NURO)

NeuroMetrix Stock (NASDAQ: NURO)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, April 19, 2024

12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights - Apr 19, 2024, 12:31PM
NeuroMetrix Appoints Joshua S. Horowitz As New Independent Director; Co. Also Terminates At-The-Market Equity Facility
Benzinga Newsdesk - Apr 19, 2024, 8:01AM

Thursday, March 14, 2024

NeuroMetrix Publishes Study Demonstrating That DPNCheck Diagnoses Diabetic Peripheral Neuropathy
Benzinga Newsdesk - Mar 14, 2024, 9:01AM

Wednesday, March 13, 2024

NeuroMetrix Announces That Over 2000 Patients With Fibromyalgia Have Been Prescribed Quell Fibromyalgia
Benzinga Newsdesk - Mar 13, 2024, 9:08AM

Monday, March 04, 2024

Echo Lake Capital Calls For The Liquidation Of Neurometrix, Inc. "Notes Tremendous Destruction Of Shareholder Value Under Co's Leadership; Sees No Reason For Co To Remain Public"
Benzinga Newsdesk - Mar 4, 2024, 8:08AM

Thursday, February 22, 2024

NeuroMetrix Q4 EPS $(1.43) Down From $(0.73) YoY, Sales $1.32M Down From $1.85M YoY
Benzinga Newsdesk - Feb 22, 2024, 7:02AM
Earnings Scheduled For February 22, 2024
Benzinga Insights - Feb 22, 2024, 5:27AM

Tuesday, February 20, 2024

NeuroMetrix 13G Filing Shows RS Fund LP Reported A 14.4% Stake In The Co As Of February 13, 2024
Benzinga Newsdesk - Feb 20, 2024, 2:58PM

Tuesday, February 13, 2024

NeuroMetrix Announces Review Of Strategic Options To Promote Growth Of Its Quell Neuromodulation And DPNCheck Neurodiagnostic Businesses And To Maximize Shareholder Value
Benzinga Newsdesk - Feb 13, 2024, 9:03AM

Tuesday, December 12, 2023

NeuroMetrix Reported The Recent Presentation Of Data From A Clinical Trial Of Quell Wearable Neuromodulation Technology In Patients With Post-Acute Covid-19 Syndrome
Benzinga Newsdesk - Dec 12, 2023, 9:03AM

Tuesday, December 05, 2023

NeuroMetrix Announces Peer-Reviewed Publication Of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy
Benzinga Newsdesk - Dec 5, 2023, 9:01AM

Wednesday, November 22, 2023

NeuroMetrix Shares Resume Trade
Benzinga Newsdesk - Nov 22, 2023, 9:00AM
NeuroMetrix Shares To Resume Trade At 9:00 A.M.. ET
Charles Gross - Nov 22, 2023, 7:40AM

Monday, November 20, 2023

NeuroMetrix Announces 1-For-8 Reverse Stock Split
Benzinga Newsdesk - Nov 20, 2023, 9:01AM

Friday, November 10, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Nov 10, 2023, 4:31PM

Thursday, October 26, 2023

NeuroMetrix shares are trading lower after the company reported Q3 financial results.
Benzinga Newsdesk - Oct 26, 2023, 11:59AM
Earnings Scheduled For October 26, 2023
Benzinga Insights - Oct 26, 2023, 7:20AM
NeuroMetrix Q3 GAAP EPS $(0.21) Up From $(0.23) YoY, Sales $1.20M Down From $1.97M YoY
Benzinga Newsdesk - Oct 26, 2023, 7:06AM

Monday, October 02, 2023

NeuroMetrix And The National Fibromyalgia Association To Collaborate To Improve The Quality Of Life For People Living With Fibromyalgia
Benzinga Newsdesk - Oct 2, 2023, 9:01AM

Tuesday, September 26, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Sep 26, 2023, 12:04PM

Monday, August 28, 2023

Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Aug 28, 2023, 1:52PM

Wednesday, August 23, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Aug 23, 2023, 1:16PM

Tuesday, August 22, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 22, 2023, 1:51PM

Monday, August 14, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 14, 2023, 1:48PM

Tuesday, August 01, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 1, 2023, 3:06PM

Thursday, July 27, 2023

NeuroMetrix Q2 EPS $(0.19) Down From $(0.17) YoY, Sales $1.65M Down From $2.14M YoY
Benzinga Newsdesk - Jul 27, 2023, 7:13AM
Earnings Scheduled For July 27, 2023
Benzinga Insights - Jul 27, 2023, 4:34AM

Thursday, June 01, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Jun 1, 2023, 12:59PM

Wednesday, May 31, 2023

NeuroMetrix Shares Quell Clinical Trial Results For Chemotherapy Induced Peripheral Neuropathy
Benzinga Newsdesk - May 31, 2023, 9:03AM

Monday, May 22, 2023

NeuroMetrix Granted European Patent Number EP3538202 Titled "'ranscutaneous Electrical Nerve Stimulation Using Novel Unbalanced Biphasic Waveform And Novel Electrode Arrangement'
Benzinga Newsdesk - May 22, 2023, 2:16PM

Wednesday, May 03, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - May 3, 2023, 1:31PM
NeuroMetrix shares are trading lower after the company reported Q1 EPS and sales results were lower year over year.
Benzinga Newsdesk - May 3, 2023, 10:22AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 3, 2023, 9:06AM
NeuroMetrix Q1 EPS $(0.20) Down From $(0.14) YoY, Sales $1.70M Down From $2.30M YoY
Benzinga Newsdesk - May 3, 2023, 7:04AM

Tuesday, March 21, 2023

NeuroMetrix To Exhibit Quell Fibromyalgia And Present New Clinical Data At The American Academy Of Pain Medicine 2023 Annual Meeting
Happy Mohamed - Mar 21, 2023, 9:11AM

Thursday, February 23, 2023

NeuroMetrix Q4 EPS $(0.09) Up From $(0.15) YoY, Sales $1.85M Up From $1.82M YoY
Benzinga Newsdesk - Feb 23, 2023, 7:01AM
Earnings Scheduled For February 23, 2023
Benzinga Insights - Feb 23, 2023, 5:18AM

Wednesday, January 25, 2023

NeuroMetrix Received Decision To Grant European Patent Titled 'TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION USING NOVEL UNBALANCED BIPHASIC WAVEFORM AND NOVEL ELECTRODE ARRANGEMENT'
Michael Horton - Jan 25, 2023, 1:15PM

Monday, January 23, 2023

NeuroMetrix Announces Launch Of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test For Peripheral Neuropathy
Benzinga Newsdesk - Jan 23, 2023, 9:16AM

Wednesday, January 11, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jan 11, 2023, 8:05AM

Tuesday, November 08, 2022

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Nov 8, 2022, 7:11AM
Why TripAdvisor Shares Are Trading Sharply Lower; Here Are 29 Stocks Moving Premarket
Lisa Levin - Nov 8, 2022, 6:08AM

Thursday, November 03, 2022

NeuroMetrix Announces Strategic Launch Of Quell Fibromyalgia
Benzinga Newsdesk - Nov 3, 2022, 9:04AM

Tuesday, November 01, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Nov 1, 2022, 11:48AM

Friday, October 28, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Oct 28, 2022, 12:12PM

Monday, October 24, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Oct 24, 2022, 11:41AM

Friday, October 21, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Oct 21, 2022, 1:26PM

Thursday, October 20, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Oct 20, 2022, 11:46AM
NeuroMetrix shares are trading lower after the company reported Q3 EPS and sales results were down year over year.
Benzinga Newsdesk - Oct 20, 2022, 9:04AM
NeuroMetrix Q3 EPS $(0.23) Down From $(0.12) YoY, Sales $2.00M Down From $2.06M YoY
Bill Haddad - Oct 20, 2022, 7:06AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved